Eli Lilly Just Delivered Another Monster Quarter. But There's More to This Story Than Weight-Loss Drugs24/7 Wall Street • 11/03/26
Eli Lilly Just Delivered Another Blowout Quarter. Is This Unstoppable Growth Stock Still a Buy?The Motley Fool • 11/02/26
After Eli Lilly's Explosive Earnings Report, Is It Too Late to Buy the Stock?The Motley Fool • 10/31/26
$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%24/7 Wall Street • 10/31/26
Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030The Motley Fool • 10/31/26
Eli Lilly Is Now Worth as Much as Warren Buffett's Berkshire Hathaway. Can the Rally Keep Going?The Motley Fool • 10/30/26
Eli Lilly's Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss Drugs24/7 Wall Street • 10/30/26
LLY Q3 Earnings Call Highlights Raised Outlook and Obesity Drug GrowthZacks Investment Research • 10/30/26
Big, fat demand for weight-loss drugs fuels Eli Lilly stock surge — as market cap hits $1.2 trillionNew York Post • 10/29/26
LLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View RaisedZacks Investment Research • 10/29/26
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher24/7 Wall Street • 10/29/26
Lilly (LLY) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 10/29/26
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases24/7 Wall Street • 10/29/26
Eli Lilly Blows Past Sales Expectations And Hikes Outlook On Mounjaro, Zepbound DominanceInvestors Business Daily • 10/29/26